Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in pulmonary hypertension associated with left ventricular systolic dysfunction
2023-507001-34-00Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension (PH) and heart failure with reduced ejection fraction (HFrEF) comparing Riociguat Bayer with Placebo for riociguat (2 arms). Primary endpoint: Change from baseline to week 16 in pulmonary artery mean pressure at rest. Started Mar 2024; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension (PH)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2023-507001-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507001-34-00.